Next Article in Journal
The Role of CD1 Gene Polymorphism in the Genetic Susceptibility to Spondyloarthropathies in the Moroccan Population and the Possible Cross-Link with Celiac Disease
Next Article in Special Issue
Encephalitis following COVID-19 Vaccination: A Systematic Review
Previous Article in Journal
Understanding the Impact of General Vaccine Attitudes on the Intent for Early COVID-19 Vaccination
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 2
10.3390/vaccines11020236
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Bell’s Palsy and COVID-19 Vaccines: A Systematic Review and Meta-Analysis

by
Khaled Albakri
1,2,
Abdulrhman Khaity
2,3,
Hany Atwan
2,4,
Othman Saleh
1,
Momen Al-Hajali
1,
Shirin Cadri
2,5,
Rehab Adel Diab
2,6,
Ebraheem Albazee
2,7,* and
Ahmed Negida
2,8,9
1
Department of Surgery, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan
2
Medical Research Group of Egypt (MRGE), Cairo 11511, Egypt
3
Department of Surgery, Faculty of Medicine, Elrazi University, Khartoum 1115, Sudan
4
Department of Surgery, Faculty of Medicine, Assiut University, Assiut 71515, Egypt
5
Department of Dermatology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Lasi, Romania
6
Department of Surgery, Faculty of Medicine, Al-Azhar University, Cairo 11651, Egypt
7
Department of Internship, Kuwait Institute for Medical Specializations (KIMS), Kuwait City 13109, Kuwait
8
Department of Surgery, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt
9
Department of Global Health, Harvard Medical School, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
Vaccines 2023, 11(2), 236; https://doi.org/10.3390/vaccines11020236
Submission received: 27 December 2022 / Revised: 13 January 2023 / Accepted: 16 January 2023 / Published: 20 January 2023
(This article belongs to the Special Issue Neurological Complications Following COVID-19 Infection and COVID-19 Vaccination)
Browse Figures
Review Reports Versions Notes

Abstract

:
Introduction: Once the COVID-19 pandemic was declared, the world was waiting for the clue that would be able to cut down the progression of the disease. Vaccines play a crucial role in reducing the disease and saving many people worldwide. However, there are several side effects of these vaccines, like pain, fatigue, fever, and neurological defects like Bell’s palsy. In this systematic review, we presented evidence about the occurrence of Bell’s palsy followed by COVID-19 vaccination. Methods: We searched PubMed, SCOPUS, EBSCO, and Web of Science (WOS) from inception till October 2022. The quality assessment was conducted using the Joanna Briggs Institute, National Institute of Health, and Newcastle-Ottawa. The analysis was conducted on SPSS. Results: Thirty-five records were involved in our study. The results of our cases revealed that most of the patients (62.8%) experienced unilateral facial paralysis. Also, the majority of the cases were reported after the first dose, and most cases were after Pfizer, AstraZeneca, and Sputnik V vaccines, respectively. The patients who were treated with corticosteroids, IVIG, and anti-viral drugs, showed marked recovery afterward. Conclusion: The rate ratio of Bell’s palsy after COVID-19 vaccination was 25.3 per 1,000,000. The ratio was higher after the first dose compared to the second dose and was higher among those who took Oxford/AstraZeneca vaccine compared to other vaccines. However, this condition was reported in a small number of cases among a large number of vaccinated people worldwide. It is important to note that the benefits of getting vaccinated far outweigh any potential risks.

1. Introduction

Once the COVID-19 pandemic was declared, the whole world was waiting for the clue that would be able to cut down the progression of the disease. Vaccines play a crucial role in reducing the disease and saving many people worldwide. As anything could have a beneficial and harmful effect and still be used as the benefits outweigh the risks, Vaccines used but underwent multiple trials to detect safety and any adverse events trying to help people in the decision regarding using the vaccine [1]. Literature showed a wide spectrum of reported complications associated with the vaccines, either neurological, cardiovascular, cerebrovascular, etc. [2,3].
This study will deal with one of the rare neurological complications associated with different types of COVID-19 vaccination, Bell’s palsy and other disorders that mimic facial palsy. Facial nerve paralysis can be reported as isolated or a part of the autoimmune disease developed with the vaccine as Guillain-Barre syndrome (GBS), Polyneuritis or other forms of autoimmune neuropathy [4]. Bell’s palsy is an idiopathic paralysis of the facial nerve with rapid onset and underdetermined etiology diagnosed by exclusion of other causes of facial nerve paralysis. Affect population with age ranging from 15 to 50 years old and able to affect males and females equally [5].
Facial paralysis associated with Bell’s palsy, if untreated, can be spontaneously resolved within 2 months by 70%, but if managed with corticosteroids, the percentage of resolution is elevated to 90% [5]. Facial palsy shows reported to be 25 cases per 100,000 per year in the general population, and Yellow card reporting systems in the United Kingdom (UK) have recorded 291 cases of facial paralysis with the Pfizer vaccine from 9 December 2020 to 5 April 2021. Although it is shown to be high, the MHRA says it is not higher than that of the general population [6]; therefore, continuous monitoring of the side effects is important. The three major vaccines in the UK, Moderna, AstraZeneca and Pfizer/BioTech, reported facial nerve palsy in their initial trials [7,8]. In the phase 3 trial of the Pfizer/BioTech vaccine, over 38,000 patients showed four cases of Bell’s palsy compared to zero reported cases in the placebo group [8]. The UK government’s website considered facial paralysis as a potential side effect of the Pfizer/BioTech vaccine; therefore, reporting cases of facial paralysis associated with the Pfizer/BioTech vaccine is important to support or exclude this theory [8].
In the phase 3 trial, safety analysis of the Moderna vaccine conducted over 30,420 patients also reported four cases of Bell’s palsy, three from the vaccine group and only one from the placebo group, while the Oxford/Astrazeneca vaccine trial conducted in over 23,745 participants reported six cases, three from vaccine group and three from the placebo group [9]. Therefore, monitoring cases of facial paralysis associated with different types of vaccines is important to detect the possible relationship between the vaccine and facial palsy. All reported cases showed the association without any causal relationship, and the U.S. Food and Drug Administration (FDA) recommends continuous monitoring to detect any possible side effects associated with the vaccines. Our study aimed to conclude and analyze the available evidence in the literature to help the researches to formulate the next research questions and continue monitor of the associated side effects with different types of the vaccine and even monitor unilateral facial nerve palsy and also help the clinicians to take the decision regarding the vaccine administration to different population taking in consideration the risks and benefits.
Recent studies suggested further evaluation of bell’s palsy and COVID-19 vaccination, and till now, there has been no strong evidence that can confidently conclude whether there is an association between bell’s palsy and COVID-19 vaccinations or not [10,11]. Furthermore, a systematic review of 17 studies was published to investigate the existence and development of COVID-19 symptoms after vaccinations [12]. They concluded that COVID-19 vaccination before SARS-COV-2 infection could reduce the risk of long-term symptoms of COVID-19.
Therefore, our aim is to specifically and comprehensively pool all records that reported the occurrence and characteristics of Bell’s Palsy after COVID-19 vaccinations.

2. Methods

We followed the guidelines of the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) when conducting this systematic review and meta-analysis. Also, this investigation was registered in the International Prospective Registration of Systematic Reviews (PROSPERO) database; [registration ID: CRD42023389393].

2.1. Literature Search Strategy

We searched PubMed, SCOPUS, EBSCO, and Web of Science from inception till October 2022. Our search strategy comprised: [ (COVID-19 OR “SARS-COV-2” OR “corona virus-19” OR “COVID-19 vaccines” OR “SARS-COV-2 vaccines” OR “ChAdOx1 nCoV-19 vaccine” OR “Astra- 89 Zeneca Vaccine” OR “Ad26.COV2. S” OR “Johnson & Johnson Vaccine”) AND (“bell palsy” OR “facial paralysis” OR “bell’s pals*” OR “acute inflammatory facial neuropathy)]. To broaden the literature search, we scanned the reference lists for eligible studies and contemporary reviews for potentially missed records. The study selection process comprised omitting duplicate records, followed by TITLE/ABSTRACT screening, then concluded by FULL-TEXT screening. Two independent co-authors completed this task, and any disagreements were solved by the primary investigators.

2.2. Eligibility Criteria and Study Selection

Studies achieving our inclusion and exclusion criteria were included: we included studies that reported (i) patients underwent any kind of COVID-19 vaccination, (ii) both genders and all age groups, (iii) the incidence and characteristics of bell’s palsy after COVID-19 vaccination, (iv) with the following study designs: case reports and case series, observational studies, and clinical trials. We excluded (i) animal, laboratory, in vitro studies, conferences, reviews, and book chapters and (ii) studies that did not mention bell’s palsy as an event.

2.3. Data Extraction

We extracted the data from each included study using a pre-specified uniform data extraction sheet. The extracted data included the following domains: study design, the number of included patients, age, sex, comorbidities, main signs and symptoms, the type of vaccine received and the number of doses, onset of fascial palsy, diagnostic tools, treatments, follow up duration and prognosis.

2.4. Quality Assessment

We have implanted the Joanna Briggs Institute (JBI) [13] and National Institute of Health (NIH) [14] quality assessment tools for our included Case reports and case series, respectively, based on the clinical characteristics, history, diagnostics, interventions and management plans with evidence score ranging from Poor, Fair or Good. Newcastle-Ottawa (NOS) [15] tool for included observational studies Cohort, Case-control and Cross-sectional studies based on selection, comparability and Outcome domains. Quality assessment is done aiming to estimate the overall evidence that our study deals with. Two Authors independently assessed the evidence and to remove the conflicts.

2.5. Statistical Analysis

The statistical analysis was conducted on SPSS. Number and percentages were used to describe the categorical variables, as well as mean and standard deviation (SD) was used to describe the continuous variables.

3. Results

After searching different databases, we obtained 430 records. After removing the duplication, 305 records underwent the first screening. Of them, 52 reports were included. (Figure 1.)
This systematic review included cohort (n = 13), case-control (n = 3), cross-sectional studies (n = 3) and self-controlled case series (n = 2) that described the rate ratio of Bell’s palsy after administration of COVID-19 vaccines. Further, this review included case reports (n = 23) and case series (n = 8), which described patients developing events of Bell’s palsy after COVID-19 vaccination (n = 105). The majority of cases were men (57.1%). The age of the patients varied from approximately 30–60 years; the average age of patients was 49.7 ± 23.2 years. The most common comorbidity among the included patients was hypertension (24.8%), followed by diabetes (16.2%) and heart failure (4.8%). According to the administrated vaccines, 49 patients took Pfizer (46.7%), while 22 (21%) and 16 (15.3%) of the cases took Sinovac Biotech and AstraZeneca, respectively. Most cases developed the symptoms after the first dose of vaccines (35.2%). The average time to symptom onset after the vaccination was 11.6 days. The majority of cases took prednisolone (38.5%). Regarding the prognosis, 36 cases (69.2%) have recovered (26 completely and 13 partially). More details can be seen in Table 1. The main clinical and pathological characteristics of the patients included in our study were summarized in Supplementary File 1, Table S7. The characteristics of the cohort, case-control, cross-sectional studies, and self-controlled case series included in this review were presented in Supplementary File 1, Table S8.
According to Table 2, the percentage of recovered females was slightly higher than recovered males (92.9% and 88.5%, respectively). All the cases who developed Bell’s palsy after the second dose recovered, while only 90% recovered among those who developed this condition after the first dose. Non-hypertensive individuals recovered at a higher rate (100%) than hypertensive ones (50%).
According to Figure 2, the rate ratio of Bell’s palsy among vaccinated groups was 25.3 per 1,000,000. The ratio was higher after the first dose compared to the second dose (Rate Ratio = 171.2 and 42.1, respectively). Patients who took the Oxford/AstraZeneca vaccine revealed higher ratios (Rate Ratio = 178.6) compared to other identified vaccines.

Quality Assessment

The overall quality assessment of the 24 included case reports based on the JBI checklist ranged from moderate to high evidence, with 17 case reports showing a low risk of bias and seven studies with a moderate risk of bias supporting their inclusion based on JBI recommendations, as shown in Table 3. The risk of bias assessment of the seven included case series based on NIH scores revealed six studies with fair-quality evidence and one with good evidence, as shown in Supplementary File 2, Table S2. The assessment of the included 15 cohort studies showed eight studies with good evidence, one with fair evidence and seven with poor evidence based on the NOS scale modified for cohort studies, as shown in Supplementary File 1, Table S3. The included seven case controls show one with fair evidence and six with high-quality evidence based on the NOS scale, as shown in Supplementary File 1, Table S4. All the included cross-sectional studies show good-quality evidence, as shown in Supplementary File 1, Table S5.

4. Discussion

4.1. Summary of the Findings

An increasing incidence of neurological disorders has escalated following COVID-19 vaccine administrations among the general population [38]. Bell’s palsy is one of these neuropathies that may have a close relationship with COVID-19 vaccines [39]. The results of our cases revealed that most of the patients (62.8%) experienced unilateral facial paralysis. The majority of the cases were reported after the first dose, and most cases were after Pfizer, AstraZeneca and Sputnik V vaccines, respectively. According to the diagnostic measures, the physical examination, MRI, and lumbar puncture were the most used in the included studies. The patients who were treated with corticosteroids, IVIG, and antiviral drugs, showed marked recovery afterward. Hypertension was the most common comorbidity among the included patients. In addition, there was a statistically significant difference between prognosis and blood pressure status.
The exact mechanism of developing facial nerve palsy following COVID-19 vaccination is yet to be unclear [40]. Multiple theories suggest the possible pathophysiology behind this phenomenon. One theory suggests the involvement of autoimmune processes either via mimicry of host molecules by the vaccine antigens or by bystander activation of autoreactive dormant T-cells [17,41]. Moreover, a study regarding the immunological activities after COVID-19 vaccine administration showed that a significant increase of antibody titers occurs following the two doses of the BNT162b2 vaccine [42]. This huge stimulation of the immune system might as well contribute to the development of Bell’s palsy [43]. Another theory states that the reactivation of different dormant viruses in the CNS might cause palsy. These viruses include the varicella-zoster virus, the Usutu virus, human herpesvirus 6 and herpes simplex virus type 1 (HSV-1). It is understood that perturbation of type I IFN signaling could lead to reactivation of the latent herpes simplex infection in neurons near the geniculate ganglion, which may prompt facial palsy (3;4). When type I IFN signaling is flawed, as it is done after vaccination with SARS-CoV-2, the capability of CD8+ T cells to retain herpes under control would also be damaged. The reactivation of HSV-1 is probably the most accepted theory [33]. A study involving 14 patients with Bell’s palsy, nine with Ramsy–Hunt syndrome, and 14 control patients, managed to show a link between the presence of the HSV-1 genome in patients and the development of Bell’s palsy [17]. In addition, it is worth mentioning that the influenza vaccine has been previously linked to an increased incidence of Bell’s palsy. The mechanism of this was also thought to be the reactivation of latent HSV-1 in the geniculate ganglion of the facial nerve, which in turn caused inflammation of the nerve [16,44]. Based on several hypotheses, the interaction between elements of the vaccine and specific human proteins’ immune cross-reactivity consequences in autoimmune disease, which may cause Bell’s palsy [45]. Innate immunity could be activated by the vaccine’s mRNA and lipids, which induce the synthesis of interferons and possibly damage the myelin sheath [41,46]. This theory was further supported by the fact that interferon therapy in hepatitis C infection patients indeed showed a rare but evident occurrence of Bell’s palsy [46,47,48]. Nevertheless, it is important to mention that Bell’s palsy can also happen secondary to GBS or other demyelinating disorders since these disorders are rare but possible adverse effects following COVID-19 vaccination [40,43]. After all, we can say that the pathophysiology of such a phenomenon could be caused by multiple factors at once and may differ from person to person, given the fact that most reported cases of Bell’s palsy after COVID-19 vaccination either show differences in the time of onset or the severity of symptoms presented [40,43].
In previous systematic reviews conducted by Shahsavarinia et al. [10] and Khurshid et al. [49], the most notable comorbidities identified among these studies were hypertension followed by diabetes and dyslipidemia, which is consistent with our study. At the same time, in the current study, we conducted the analytical test to determine the discrepancy between the variables and prognosis. Although there was no statistically significant difference concerning the prognosis and most of the comorbidities, patients without hyperuricemia or hypertension had a high rate of full recuperation in comparison with patients with these diseases. Our findings are in the same direction as the former reviews performed by Sriwastava et al. [50] and Shahsavarinia et al. [10] in terms of the association between the type of vaccines and the incidence of facial palsy. Unlikely, Khurshid et al. [49] reported that most of the cases had bell’s palsy after taking the AstraZeneca vaccine. This could be elucidated by the variation in sample size and baseline characteristics. However, our results are in agreement with Khurshid et al. [49] in the case that the majority of symptoms have appeared following the first dose of the vaccines.
The average time from vaccination to onset of symptoms amongst the cases in our review was 11.49 (11.064) days. This is consistent with previous studies by Shahsavarinia et al. [10] that mentioned the onset of symptoms of bell’s palsy at around 10 days post-vaccination. On the other hand, our study represented that (62.8%) of the patients had unilateral-side complaints. As evidenced by Khurshid et al. [49], most of the patients (53.45%) presented with bilateral facial weakness.
Diagnosis of any facial palsy cases is often based on physical examination and is confirmed through electromyography, lumbar puncture, CT, and MRI. In our systematic review, (95.35%) of the cases were diagnosed through physical examination, (67.44%) using MRI, and (48.84%) by lumbar puncture. In contrast, Khurshid et al. [49] study documented the majority of the included patients were diagnosed by CSF analysis and then by CT and MRI. This can be attributed to the fact that most participants in this study may have different characteristics from Khurshid et al. study [49]. Regarding the management, (46.51%) and (32.5%) of the patients in our study who received corticosteroids and IVIG therapy, respectively, have more quick mitigation of the symptoms. This result was also identified in another systematic review by Khurshid et al. [49].
Generally, the incidence of neurological diseases after vaccination varies depending on demographic features, residual confounding, type of vaccines, and reporting bias that may have a potential impact on the consequences [51]. It is critical to highlight that the causality relationship between Bell’s palsy and COVID-19 vaccines is not confirmed yet. Therefore, we recommend conducting further studies in an attempt to conclude the possibility of synergistic influence between facial palsy and COVID-19 vaccines.

4.2. Limitations and Strengths of the Study

The major limitations in this study have been related to a limited number of included studies that assessed the association between facial palsy and COVID-19 vaccines. Hence, the small sample size, which is reflected in the strength of the evidence. Nevertheless, the strengths of our study are as follows: (1) our systematic review provided the analytical investigation between the variables and prognosis of patients with bell’s palsy after commencing the vaccination, (2) we provided a more comprehensive analysis in an attempt to summarize the probability association between COVID-19 vaccines and facial palsy.

5. Conclusions

The rate ratio of Bell’s palsy after COVID-19 vaccination was 25.3 per 1,000,000. The ratio was higher after the first dose compared to the second dose and was higher among those who took the Oxford/AstraZeneca vaccine compared to other vaccines. The average time to symptom onset after the vaccination was 11.6 days. Hypertension was the most common comorbidity among the included patients. Moreover, prednisone was the most frequent drug used to manage this condition. Overall, the majority of the patients recovered. However, this condition was reported in a small number of cases among a large number of vaccinated people worldwide. Additionally, it is important to note that the COVID-19 vaccine has been shown to be safe and effective in preventing illness as well as the benefits of getting vaccinated far outweigh any potential risks.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines11020236/s1. Table S1: the quality assessment of included case reports using the (JBI) Quality Assessment Tool. Table S2: the quality assessment of included case series studies using the (NIH) Quality Assessment Tool. Table S3: the quality assessment of included self-controlled case series studies using the (NIH) Quality Assessment Tool. Table S4: the quality assessment of included cohort studies using the (NOS) Quality Assessment Tool. Table S5: the quality assessment of included case-control studies using the (NOS) Quality Assessment Tool. Table S6: the quality assessment of included cross-sectional studies using the (NOS) Quality Assessment Tool. Table S7: the main clinical and pathological characteristics of the included patients. Table S8: the characteristics of the cohort, case-control, and cross-sectional studies and self-controlled case series included in our systematic review.

Author Contributions

Conceptualization, K.A., E.A. and A.N.; methodology, K.A., A.K., H.A., O.S., M.A.-H., S.C. and R.A.D.; software, K.A. and A.N.; validation, K.A., E.A. and A.N.; formal analysis, K.A. and A.N.; investigation, K.A., A.K., H.A., O.S., M.A.-H., S.C., R.A.D. and E.A.; resources, A.K. and S.C.; data curation, K.A., A.K., H.A., O.S., M.A.-H., S.C., R.A.D., E.A. and A.N.; writing—original draft preparation, K.A., A.K., H.A., O.S., M.A.-H., S.C., R.A.D., E.A. and A.N.; writing—review and editing, E.A. and A.N.; visualization, A.N.; supervision, E.A. and A.N.; project administration, K.A. and E.A.; funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

All authors declare they receive no fund.

Institutional Review Board Statement

Not applicable because this study based on published records.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. COVID-19 Vaccine AstraZeneca: Benefits Still Outweigh the Risks Despite Possible Link to Rare bBlood cClots with Low Blood Platelets | European Medicines Agency. Available online: https://www.ema.europa.eu/en/news/COVID-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots (accessed on 19 December 2022).
  2. Ercoli, T.; Lutzoni, L.; Orofino, G.; Muroni, A.; Defazio, G. Functional neurological disorder after COVID-19 vaccination. Neurol. Sci. 2021, 42, 3989–3990. [Google Scholar] [CrossRef] [PubMed]
  3. Garg, R.K.; Paliwal, V.K. Spectrum of neurological complications following COVID-19 vaccination. Neurol. Sci. 2022, 43, 3–40. [Google Scholar] [CrossRef] [PubMed]
  4. Hampton, L.M.; Aggarwal, R.; Evans, S.J.W.; Law, B. General determination of causation between COVID-19 vaccines and possible adverse events. Vaccine 2021, 39, 1478–1480. [Google Scholar] [CrossRef] [PubMed]
  5. Zandian, A.; Osiro, S.; Hudson, R.; Ali, I.M.; Matusz, P.; Tubbs, S.R.; Loukas, M. The neurologist’s dilemma: A comprehensive clinical review of Bell’s palsy, with emphasis on current management trends. Med. Sci. Monit. 2014, 20, 83–90. [Google Scholar] [CrossRef] [Green Version]
  6. The Pfizer BioNTech (BNT162b2) COVID-19 Vaccine: What yYou Need to Know. Available online: https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-COVID-19--vaccine-what-you-need-to-know (accessed on 19 December 2022).
  7. Regulatory Approval of COVID-19 Vaccine AstraZeneca - GOV.UK. Available online: https://www.gov.uk/government/publications/regulatory-approval-of-COVID-19-vaccine-astrazeneca (accessed on 19 December 2022).
  8. ARCHIVE: Information for UK recipients on Pfizer/BioNTech COVID-19 vaccine (Regulation 174) - GOV.UK. Available online: https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-COVID-19/information-for-uk-recipients-on-pfizerbiontech-COVID-19-vaccine (accessed on 19 December 2022).
  9. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. COVE Study Group Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef]
  10. Shahsavarinia, K.; Mahmoodpoor, A.; Sadeghi-Ghyassi, F.; Nedayi, A.; Razzaghi, A.; Zehi Saadat, M.; Salehi-Pourmehr, H. Bell’s Palsy and COVID-19 Vaccination: A Systematic Review. Med. J. Islam. Repub. Iran 2022, 36, 85. [Google Scholar] [CrossRef]
  11. Cirillo, N.; Doan, R. The association between COVID-19 vaccination and Bell’s palsy. Lancet Infect. Dis. 2022, 22, 5–6. [Google Scholar] [CrossRef]
  12. Notarte, K.I.; Catahay, J.A.; Velasco, J.V.; Pastrana, A.; Ver, A.T.; Pangilinan, F.C.; Peligro, P.J.; Casimiro, M.; Guerrero, J.J.; Gellaco, M.M.L.; et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine 2022, 53, 101624. [Google Scholar] [CrossRef]
  13. The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for... | Download Scientific Diagram. Available online: https://www.researchgate.net/figure/The-Joanna-Briggs-Institute-JBI-critical-appraisal-checklist-for-studies-reporting_fig2_322317583 (accessed on 19 December 2022).
  14. NIH Quality Assessment Tool for Case Series/Case Reports | Download Scientific Diagram. Available online: https://www.researchgate.net/figure/NIH-quality-assessment-tool-for-case-series-case-reports_tbl3_344087387 (accessed on 19 December 2022).
  15. Ottawa Hospital Research Institute. Available online: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 19 December 2022).
  16. Burrows, A.; Bartholomew, T.; Rudd, J.; Walker, D. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. BMJ Case Rep. 2021, 14. [Google Scholar] [CrossRef]
  17. Cellina, M.; D’Arrigo, A.; Floridi, C.; Oliva, G.; Carrafiello, G. Left Bell’s palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine: A case report. Clin. Imaging 2022, 82, 1–4. [Google Scholar] [CrossRef]
  18. Čenščák, D.; Ungermann, L.; Štětkářová, I.; Ehler, E. Guillan-Barré Syndrome after First Vaccination Dose against COVID-19: Case Report. Acta Medica (Hradec Kralove) 2021, 64, 183–186. [Google Scholar] [CrossRef] [PubMed]
  19. Cirillo, N.; Orlandi, M.; Colella, G. Patients with post-COVID-19 vaccination facial palsy: To boost or not to boost? Transl. Neurosci. 2022, 13, 236–239. [Google Scholar] [CrossRef] [PubMed]
  20. Colella, G.; Orlandi, M.; Cirillo, N. Bell’s palsy following COVID-19 vaccination. J. Neurol. 2021, 268, 3589–3591. [Google Scholar] [CrossRef] [PubMed]
  21. Finsterer, J. Exacerbating Guillain-Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination. Case Rep. Infect. Dis. 2021, 2021, 3619131. [Google Scholar] [CrossRef] [PubMed]
  22. Iftikhar, H.; Noor, S.M.U.; Masood, M.; Bashir, K. Bell’s Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine. Cureus 2021, 13, e15935. [Google Scholar] [CrossRef] [PubMed]
  23. Introna, A.; Caputo, F.; Santoro, C.; Guerra, T.; Ucci, M.; Mezzapesa, D.M.; Trojano, M. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? Clin. Neurol. Neurosurg. 2021, 208, 106887. [Google Scholar] [CrossRef] [PubMed]
  24. Ish, S.; Ish, P. Facial nerve palsy after COVID-19 vaccination - A rare association or a coincidence. Indian J. Ophthalmol. 2021, 69, 2550–2552. [Google Scholar] [CrossRef]
  25. Manea, M.M.; Dragoș, D.; Enache, I.; Sirbu, A.G.; Tuta, S. Multiple cranial nerve palsies following COVID-19 vaccination-Case report. Acta Neurol. Scand. 2022, 145, 257–259. [Google Scholar] [CrossRef]
  26. Martin-Villares, C.; Vazquez-Feito, A.; Gonzalez-Gimeno, M.J.; de la Nogal-Fernandez, B. Bell’s palsy following a single dose of mRNA SARS-CoV-2 vaccine: A case report. J. Neurol. 2022, 269, 47–48. [Google Scholar] [CrossRef]
  27. Mason, M.C.; Liaqat, A.; Morrow, J.; Basso, R.; Gujrati, Y. Bilateral Facial Nerve Palsy and COVID-19 Vaccination: Causation or Coincidence? Cureus 2021, 13, e17602. [Google Scholar] [CrossRef]
  28. Mussatto, C.C.; Sokol, J.; Alapati, N. Bell’s palsy following COVID-19 vaccine administration in HIV+ patient. Am. J. Ophthalmol. Case Rep. 2022, 25, 101259. [Google Scholar] [CrossRef] [PubMed]
  29. Nasuelli, N.A.; De Marchi, F.; Cecchin, M.; De Paoli, I.; Onorato, S.; Pettinaroli, R.; Savoini, G.; Godi, L. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. Neurol. Sci. 2021, 42, 4747–4749. [Google Scholar] [CrossRef] [PubMed]
  30. Nishizawa, Y.; Hoshina, Y.; Baker, V. Bell’s palsy following the Ad26.COV2.S COVID-19 vaccination. QJM 2021, 114, 657–658. [Google Scholar] [CrossRef] [PubMed]
  31. Obermann, M.; Krasniqi, M.; Ewers, N.; Fayad, J.; Haeberle, U. Bell’s palsy following COVID-19 vaccination with high CSF antibody response. Neurol. Sci. 2021, 42, 4397–4399. [Google Scholar] [CrossRef]
  32. Pothiawala, S. Bell’s Palsy After Second Dose of Moderna COVID-19 Vaccine: Coincidence or Causation? Acta Med. Litu. 2021, 28, 298–301. [Google Scholar] [CrossRef]
  33. Poudel, S.; Nepali, P.; Baniya, S.; Shah, S.; Bogati, S.; Nepal, G.; Ojha, R.; Edaki, O.; Lazovic, G.; Kara, S. Bell’s palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19. Ann. Med. Surg. 2022, 78, 103897. [Google Scholar] [CrossRef]
  34. Repajic, M.; Lai, X.L.; Xu, P.; Liu, A. Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy. Brain Behav. Immun. Health 2021, 13, 100217. [Google Scholar] [CrossRef]
  35. Shalabi, F.; Lossos, A.; Karussis, D. A case report of unilateral cervical lymphadenopathy and multiple cranial neuropathies following mRNA-COVID-19 vaccination. BMC Neurol. 2022, 22, 369. [Google Scholar] [CrossRef]
  36. Yu, B.-Y.; Cen, L.-S.; Chen, T.; Yang, T.-H. Bell’s palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell’s palsy: A case report. World J. Clin. Cases 2021, 9, 8274–8279. [Google Scholar] [CrossRef]
  37. Zhang, H.; Sanchez Gomez, D.; Repajic, M.; Liu, A.K. Another Case of Bell’s Palsy Recurrence After Pfizer-BioNTech COVID-19 Vaccination. Cureus 2022, 14, e27422. [Google Scholar] [CrossRef]
  38. Dutta, S.; Kaur, R.; Charan, J.; Bhardwaj, P.; Ambwani, S.R.; Babu, S.; Goyal, J.P.; Haque, M. Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines. Cureus 2022, 14, e21376. [Google Scholar] [CrossRef]
  39. Renoud, L.; Khouri, C.; Revol, B.; Lepelley, M.; Perez, J.; Roustit, M.; Cracowski, J.-L. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern. Med. 2021, 181, 1243–1245. [Google Scholar] [CrossRef] [PubMed]
  40. Wan, E.Y.F.; Chui, C.S.L.; Lai, F.T.T.; Chan, E.W.Y.; Li, X.; Yan, V.K.C.; Gao, L.; Yu, Q.; Lam, I.C.H.; Chun, R.K.C.; et al. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: A case series and nested case-control study. Lancet Infect. Dis. 2022, 22, 64–72. [Google Scholar] [CrossRef] [PubMed]
  41. Ozonoff, A.; Nanishi, E.; Levy, O. Bell’s palsy and SARS-CoV-2 vaccines. Lancet Infect. Dis. 2021, 21, 450–452. [Google Scholar] [CrossRef]
  42. Khoury, D.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.; Wheatley, A.K.; Juno, J.A.; Subbarao, K.; Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021, 27, 1205–1211. [Google Scholar] [CrossRef] [PubMed]
  43. Wan, E.Y.F.; Chui, C.S.L.; Ng, V.W.S.; Wang, Y.; Yan, V.K.C.; Lam, I.C.H.; Fan, M.; Lai, F.T.T.; Chan, E.W.Y.; Li, X.; et al. mRNA (BNT162b2) COVID-19 vaccination increased risk of Bell’s palsy: A nested case control and self-controlled case series study. Clin. Infect. Dis. 2022. [Google Scholar] [CrossRef]
  44. Ahsanuddin, S.; Nasser, W.; Roy, S.C.; Povolotskiy, R.; Paskhover, B. Facial paralysis and vaccinations: A vaccine adverse event reporting system review. Fam. Pract. 2022, 39, 80–84. [Google Scholar] [CrossRef]
  45. Seneff, S.; Nigh, G.; Kyriakopoulos, A.M.; McCullough, P.A. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem. Toxicol. 2022, 164, 113008. [Google Scholar] [CrossRef] [PubMed]
  46. Bekkali, N.; Allard, T.; Lengellé, C.; Estève, E. Eczematiform eruption after Pfizer-BioNTech COVID-19 vaccine. Therapie 2021, 76, 364–365. [Google Scholar] [CrossRef]
  47. Hwang, I.; Calvit, T.B.; Cash, B.D.; Holtzmuller, K.C. Bell’s palsy: A rare complication of interferon therapy for hepatitis C. Dig. Dis. Sci. 2004, 49, 619–620. [Google Scholar] [CrossRef]
  48. Shemer, A.; Pras, E.; Einan-Lifshitz, A.; Dubinsky-Pertzov, B.; Hecht, I. Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study. JAMA Otolaryngol. Head Neck Surg. 2021, 147, 739–743. [Google Scholar] [CrossRef] [PubMed]
  49. Khurshid, M.; Ansari, I.; Ahmad, H.; Ghaffar, H.; Khurshid, A.; Shahid, A.; Essar, M.Y.; Ullah, I.; Cheema, H.A. Development of facial palsy following COVID-19 vaccination: A systematic review. Ann. Med. Surg. (Lond.) 2022, 82, 104758. [Google Scholar] [CrossRef] [PubMed]
  50. Sriwastava, S.; Sharma, K.; Khalid, S.H.; Bhansali, S.; Shrestha, A.K.; Elkhooly, M.; Srivastava, S.; Khan, E.; Jaiswal, S.; Wen, S. COVID-19 Vaccination and Neurological Manifestations: A Review of Case Reports and Case Series. Brain Sci. 2022, 12, 407. [Google Scholar] [CrossRef] [PubMed]
  51. Noseda, R.; Ripellino, P.; Ghidossi, S.; Bertoli, R.; Ceschi, A. Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase. Vaccines 2021, 9, 1022. [Google Scholar] [CrossRef]
Vaccines 11 00236 g001 550
Figure 1. Shows the PRISMA flow diagram of the included studies.
Figure 1. Shows the PRISMA flow diagram of the included studies.
Vaccines 11 00236 g001
Vaccines 11 00236 g002 550
Figure 2. Represents the frequency of Bell’s palsy per 1,000,000 individuals after COVID-19 vaccination.
Figure 2. Represents the frequency of Bell’s palsy per 1,000,000 individuals after COVID-19 vaccination.
Vaccines 11 00236 g002
Table
Table 1. Characteristics of the patients.
Table 1. Characteristics of the patients.
Frequency (n)Percentage (%)
Characteristics (n = 105)
Age, mean (SD)49.7 (23.2)
SexMale6057.1
Female4542.9
Comorbidities
Chronic kidney diseaseNA1110.5
No9388.6
Yes10.9
HIVNA1110.5
No9388.6
Yes10.9
DiabetesNA4946.7
No3937.1
Yes1716.2
HypertensionNA4643.8
No3331.4
Yes2624.8
DyslipidemiaNA1110.5
No9186.7
Yes32.8
AsthmaNA1110.5
No9287.6
Yes21.9
MigraineNA1110.5
No9388.6
Yes10.9
HyperuricemiaNA1110.5
No9388.6
Yes10.9
ObesityNA1110.5
No9388.6
Yes10.9
Heart failureNA5956.2
No4139
Yes54.8
Thyroid dysfunctionNA1110.5
No9388.6
Yes10.9
CancerNA1110.5
No9388.6
Yes10.9
PoliomyelitisNA1110.5
No9388.6
Yes10.9
StrokeNA1110.5
No9388.6
Yes10.9
Obstructive sleep apneaNA1110.5
No9388.6
Yes10.9
Meniere’s diseaseNA1110.5
No9388.6
Yes10.9
Vaccines
Type of given vaccineNA10.9
Moderna65.7
Pfizer4946.7
AstraZeneca1615.3
Sinovac Biotech2221
Johnson & Johnson21.9
Sputnik V76.7
Vector based vaccine10.9
COVAXIN10.9
Doses
Dosage resulted in the symptomsNA5754.3
13735.2
21110.5
Diagnostic tools, treatments, and prognosis (n = 52)
Diagnostic tools
Physical examinationNA11.9
No23.8
Yes4994.2
CTNo4484.6
Yes815.4
MRINo2344.2
Yes2955.8
EMGNo4688.5
Yes611.5
Nerve conductionNo4790.4
Yes59.6
Lumbar punctureNo3159.6
Yes2140.4
ElectrophoresisNA11.9
No3975
Yes1223.1
Treatments
PrednisoneNA1121.2
No2140.4
Yes2038.5
MethylprednisoloneNA1121.2
No3873.1
Yes35.8
DeflazacortNA1121.2
No4076.9
Yes11.9
IVIGNA1121.2
No2751.9
Yes1426.9
Anti-viralNA1121.2
No3465.4
Yes713.5
Plasma exchangeNA1121.2
No4076.9
Yes11.9
Follow-up time, mean (SD)30.19 (72.55)
Outcome
The affected side of the faceUnilateral3669.2
Bilateral1630.8
Time of symptoms onset (days), mean (SD)11.6 (11.13)
PrognosisNA1221.2
No response59.6
Partial response1325
Complete response2344.2
Overall prognosisNA1221.2
Not Recovered59.6
Recovered3669.2
Table
Table 2. Represents the possible factors affecting the prognosis of the COVID-19 vaccine-induced Bell’s palsy (n = 40).
Table 2. Represents the possible factors affecting the prognosis of the COVID-19 vaccine-induced Bell’s palsy (n = 40).
CharacteristicsNot Recovered n (%)Recovered n (%)
Gender
Male3 (11.5)23 (88.5)
Female1 (7.1)13 (92.9)
Age
<401 (6.7)14 (93.3)
≥403 (12)22 (88)
Affected side
Unilateral1 (4.2)23 (95.8)
Bilateral3 (18.8)13 (81.3)
Doses
The dose that led to the symptoms
NA1 (25)3 (75)
First3 (10)27 (90)
Second0 (0.0)6 (100)
Vaccines
Type of vaccine
NA0 (0.0)1 (100)
Moderna0 (0.0)5 (100)
Pfizer1 (8.3)11 (91.7)
AstraZeneca2 (18.2)9 (81.8)
Sinovac Biotech0 (0.0)1 (100)
Johnson & Johnson0 (0.0)1 (100)
Sputnik V1 (14.3)6 (85.7)
Vector based vaccine0 (0.0)1 (100)
COVAXIN0 (0.0)1 (100)
Comorbidities
Chronic Kidney disease
NA2 (18.2)9 (81.8)
No2 (7.1)26 (92.9)
Yes0 (0.0)1 (100)
HIV
NA2 (18.2)9 (81.8)
No2 (7.1)26 (92.9)
Yes0 (0.0)1 (100)
Diabetes
NA2 (18.2)9 (81.8)
No2 (7.1)26 (92.9)
Yes0 (0.0)1 (100)
Hypertension
NA2 (18.2)9 (81.8)
No0 (0.0)25 (100)
Yes2 (50)2 (50)
Dyslipidemia
NA2 (18.2)9 (81.8)
No2 (7.1)26 (92.9)
Yes0 (0.0)1 (100)
Asthma
NA2 (18.2)9 (81.8)
No2 (7.1)26 (92.9)
Yes0 (0.0)1 (100)
Migraine
NA2 (18.2)9 (81.8)
No2 (7.1)26 (92.9)
Yes0 (0.0)1 (100)
Hyperuricemia
NA2 (18.2)9 (81.8)
No1 (3.6)27 (96.4)
Yes1 (100)0 (0.0)
Obesity
NA2 (18.2)9 (81.8)
No2 (7.1)26 (92.9)
Yes0 (0.0)1 (100)
Heart disease
NA2 (18.2)9 (81.8)
No2 (6.9)27 (93.1)
Thyroid dysfunction
NA2 (18.2)9 (81.8)
No2 (7.1)26 (92.9)
Yes0 (0.0)1 (100)
Cancer
NA2 (18.2)9 (81.8)
No2 (6.9)27 (93.1)
Poliomyelitis
NA2 (18.2)9 (81.8)
No2 (7.1)26 (92.9)
Yes0 (0.0)1 (100)
Stroke
NA2 (18.2)9 (81.8)
No2 (6.9)27 (93.1)
Obstructive sleep apnea
NA2 (18.2)9 (81.8)
No2 (6.9)27 (93.1)
Meniere’s disease
NA2 (18.2)9 (81.8)
No2 (6.9)27 (93.1)
Treatments
Prednisone
NA0 (0.0)2 (100)
No3 (15)17 (85)
Yes1 (5.6)17 (94.4)
Methylprednisolone
NA0 (0.0)2 (100)
No4 (11.4)31 (88.6)
Yes0 (0.0)3 (100)
Deflazacort
NA0 (0.0)2 (100)
No4 (10.8)33 (89.2)
Yes0 (0.0)1 (100)
IVIG
NA0 (0.0)2 (100)
No2 (8.3)22 (91.7)
Yes2 (14.3)12 (85.7)
Anti-viral
NA0 (0.0)2 (100)
No4 (12.5)28 (87.5)
Yes0 (0.0)6 (100)
Plasma exchange
NA0 (0.0)2 (100)
No4 (10.8)33 (89.2)
Yes0 (0.0)1 (100)
Table
Table 3. The quality assessment of the included case reports using the (JBI) Quality Assessment Tool.
Table 3. The quality assessment of the included case reports using the (JBI) Quality Assessment Tool.
Study IDThe Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case ReportsTotal Quality Score, (%)
Q (1)Q (2)Q (3)Q (4)Q (5)Q (6)Q (7)Q (8)
Burrows 2021 [16] YESYESYESYESYESYESNOYES88%
Cellina 2022 [17] YESYESYESYESYESYESNOYES88%
Čenščák 2021 [18] YESYESYESYESYESYESNOYES88%
Cirillo 2022 [19]NONOYESYESYESYESNOYES62.50%
Colella 2021 [20] YESYESYESNOYESYESNOYES75%
Ercoli 2021 [2]YESYESYESYESYESYESNOYES88%
Finsterer 2021 [21] YESYESYESYESYESYESNOYES88%
Iftikhar 2021 [22] YESYESYESYESYESYESNOYES88%
Introna 2021 [23] YESYESYESYESYESYESNOYES88%
Ish 2021 [24] YESNOYESNOYESYESNOYES62.50%
Manea 2021 [25] YESYESYESYESYESYESNOYES88%
Martin-Villares 2021 [26]NOYESYESYESNOYESNOYES75%
Mason 2021 [27] YESNOYESYESYESYESNOYES75%
Mussatto2021 [28] YESNOYESYESYESYESNOYES75%
Nasuelli 2021 [29] YESNOYESYESYESYESNOYES75%
Nishizawa 2021 [30] YESYESYESYESNONONOYES62.50%
Obermann 2021 [31] YESYESYESYESYESYESNOYES88%
Pothiawala 2021 [32] YESYESYESNOYESNONOYES62.50%
Poudel 2022 [33] YESNOYESYESYESYESNOYES75%
Repajic 2021 [34] YESYESYESNOYESYESNOYES75%
Shalabi 2022 [35] YESNOYESYESYESYESNOYES75%
Yu 2021 [36] YESNOYESYESYESYESNOYES75%
Zhang 2022 [37] YESNOYESNOYESYESNOYES62.50%
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Albakri, K.; Khaity, A.; Atwan, H.; Saleh, O.; Al-Hajali, M.; Cadri, S.; Diab, R.A.; Albazee, E.; Negida, A. Bell’s Palsy and COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Vaccines 2023, 11, 236. https://doi.org/10.3390/vaccines11020236

AMA Style

Albakri K, Khaity A, Atwan H, Saleh O, Al-Hajali M, Cadri S, Diab RA, Albazee E, Negida A. Bell’s Palsy and COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Vaccines. 2023; 11(2):236. https://doi.org/10.3390/vaccines11020236

Chicago/Turabian Style

Albakri, Khaled, Abdulrhman Khaity, Hany Atwan, Othman Saleh, Momen Al-Hajali, Shirin Cadri, Rehab Adel Diab, Ebraheem Albazee, and Ahmed Negida. 2023. "Bell’s Palsy and COVID-19 Vaccines: A Systematic Review and Meta-Analysis" Vaccines 11, no. 2: 236. https://doi.org/10.3390/vaccines11020236

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop